ORGANOGENESIS HOLDINGS INC. Interest Expense
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Interest Expense of $620.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-08
- ORGANOGENESIS HOLDINGS INC. interest expense for the quarter ending 2024-06-30 was $620.00K, a 4.38% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. interest expense for the quarter ending 2024-03-31 was $514.00K, a 20.80% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. interest expense for the quarter ending 2023-12-31 was $502.00K.
- ORGANOGENESIS HOLDINGS INC. interest expense for the quarter ending 2023-09-30 was $444.00K, a 22.38% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. interest expense for fiscal 2023 was $2.19M, a 9.01% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. interest expense for fiscal 2022 was $2.01M, a 72.24% decline from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. interest expense for fiscal 2021 was $7.24M, a 35.85% decline from fiscal 2020.
- ORGANOGENESIS HOLDINGS INC. interest expense for fiscal 2020 was $11.28M, a 25.38% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-06-30 | $620.00K 10-Q · filed 2024-08-08 | $1.13M 10-Q · filed 2024-08-08 | $1.64M derived: sum of 3 quarters · filed 2024-08-08 | $2.08M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2024-03-31 | $514.00K 10-Q · filed 2024-05-09 | $1.02M derived: sum of 2 quarters · filed 2024-05-09 | $1.46M derived: sum of 3 quarters · filed 2024-05-09 | $2.05M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $946.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.54M derived: sum of 3 quarters · filed 2024-08-08 | $2.19M 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $444.00K 10-Q · filed 2023-11-09 | $1.04M derived: sum of 2 quarters · filed 2024-08-08 | $1.69M 10-Q · filed 2023-11-09 | $1.66M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-06-30 | $594.00K 10-Q · filed 2024-08-08 | $1.24M 10-Q · filed 2024-08-08 | $1.21M derived: sum of 3 quarters · filed 2024-08-08 | $1.78M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $649.00K 10-Q · filed 2024-05-09 | $619.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.19M derived: sum of 3 quarters · filed 2024-05-09 | $1.92M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $542.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.27M derived: sum of 3 quarters · filed 2024-02-29 | $2.01M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $572.00K 10-Q · filed 2023-11-09 | $1.30M derived: sum of 2 quarters · filed 2023-11-09 | $2.04M 10-Q · filed 2023-11-09 | $2.89M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $730.00K 10-Q · filed 2023-08-09 | $1.47M 10-Q · filed 2023-08-09 | $2.32M derived: sum of 3 quarters · filed 2024-02-29 | $3.80M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $737.00K 10-Q · filed 2023-05-10 | $1.59M derived: sum of 2 quarters · filed 2024-02-29 | $3.07M derived: sum of 3 quarters · filed 2024-02-29 | $5.50M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.33M derived: sum of 2 quarters · filed 2024-02-29 | $4.77M derived: sum of 3 quarters · filed 2024-02-29 | $7.24M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $1.48M 10-Q · filed 2022-11-09 | $3.91M derived: sum of 2 quarters · filed 2022-11-09 | $6.38M 10-Q · filed 2022-11-09 | $9.27M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $2.43M 10-Q · filed 2022-08-09 | $4.90M 10-Q · filed 2022-08-09 | $7.79M derived: sum of 3 quarters · filed 2023-03-01 | $10.76M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $2.47M 10-Q · filed 2022-05-10 | $5.36M derived: sum of 2 quarters · filed 2023-03-01 | $8.33M derived: sum of 3 quarters · filed 2023-03-01 | $11.24M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $5.86M derived: sum of 2 quarters · filed 2023-03-01 | $8.77M derived: sum of 3 quarters · filed 2023-03-01 | $11.28M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $2.97M 10-Q · filed 2021-11-09 | $5.88M derived: sum of 2 quarters · filed 2021-11-09 | $8.39M 10-Q · filed 2021-11-09 | $10.99M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $2.91M 10-Q · filed 2021-08-09 | $5.42M 10-Q · filed 2021-08-09 | $8.03M derived: sum of 3 quarters · filed 2022-03-01 | $10.45M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $2.51M 10-Q · filed 2021-05-11 | $5.11M derived: sum of 2 quarters · filed 2022-03-01 | $7.54M derived: sum of 3 quarters · filed 2022-03-01 | $9.73M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.03M derived: sum of 2 quarters · filed 2022-03-01 | $7.22M derived: sum of 3 quarters · filed 2022-03-01 | $9.00M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $2.43M 10-Q · filed 2020-11-09 | $4.61M derived: sum of 2 quarters · filed 2020-11-09 | $6.39M 10-Q · filed 2020-11-09 | $9.05M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $2.19M 10-Q · filed 2020-08-10 | $3.96M 10-Q · filed 2020-08-10 | $6.63M derived: sum of 3 quarters · filed 2020-08-10 | $9.57M derived: sum of 4 quarters · filed 2020-08-10 | ||
| 2019-03-31 | $1.78M 10-Q · filed 2020-05-11 | $1.80M 10-Q · filed 2019-05-10 | $4.44M derived: sum of 2 quarters · filed 2020-05-11 | $7.38M derived: sum of 3 quarters · filed 2020-05-11 | $10.16M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $2.66M 10-K · filed 2019-03-18 | $5.60M derived: sum of 2 quarters · filed 2019-11-12 | $8.38M derived: sum of 3 quarters · filed 2019-11-12 | $10.79M 10-K · filed 2021-03-16 | $10.85M 10-K · filed 2019-03-18 | |
| 2018-09-30 | $2.94M 10-Q · filed 2019-11-12 | $2.96M 10-K · filed 2019-03-18 | $5.72M derived: sum of 2 quarters · filed 2019-11-12 | $8.13M 10-Q · filed 2019-11-12 | $10.43M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $2.78M 10-Q · filed 2019-08-09 | $2.80M 10-K · filed 2019-03-18 | $5.19M 10-Q · filed 2019-08-09 | $7.49M derived: sum of 3 quarters · filed 2019-08-09 | $9.73M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-03-31 | $2.43M 10-Q · filed 2019-05-10 | $4.71M derived: sum of 2 quarters · filed 2019-05-10 | $6.95M derived: sum of 3 quarters · filed 2019-05-10 | $8.98M derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | $2.28M 10-K · filed 2019-03-18 | $4.52M derived: sum of 2 quarters · filed 2019-03-18 | $6.55M derived: sum of 3 quarters · filed 2019-03-18 | $8.01M 10-K · filed 2020-03-09 | $8.14M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $2.23M 10-K · filed 2019-03-18 | $4.26M derived: sum of 2 quarters · filed 2019-03-18 | $5.86M derived: sum of 3 quarters · filed 2019-03-18 | |||
| 2017-06-30 | $2.03M 10-K · filed 2019-03-18 | $3.62M derived: sum of 2 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $1.59M 10-K · filed 2019-03-18 | |||||
| 2016-12-31 | $5.63M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |